Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency

Protein Science

Volumn 17, Issue 4, 2008, Pages 633-643

  Dwyer, John J ^a   Wilson, Karen L ^a   Martin, Kimberly ^a   Seedorff, Jennifer E ^a   Hasan, Aisha ^a   Medinas, Robyn J ^a   Davison, Donna K ^a   Feese, Michael D ^b,c   Richter, Hans Thomas ^b,c   Kim, Hidong ^b   Matthews, Thomas J ^a   Delmedico, Mary K ^a  

^a Trimeris Inc   (United States)

^b DeCODE Chemistry & Biostructures   (United States)

^c deCODE Biostructures Inc ^*  (United States)

Author keywords

Antiviral; Coiled coil; Fusion inhibitor; gp41; HIV; N peptide; Protein design

Indexed keywords

ENFUVIRTIDE; PROTEIN GP41; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN TARGETING; STRUCTURE ANALYSIS; THERMOSTABILITY; VIRUS RESISTANCE;

CELLS, CULTURED; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE, QUATERNARY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41649121143     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.073307608     Document Type: Article

References (59)

1. Bewley, C.A., Louis, J.M., Ghirlando, R., and Clore, G.M. 2002. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J. Biol. Chem. 277: 14238-14245.
2. Bianchi, E., Finotto, M., Ingallinella, P., Hrin, R., Carella, A.V., Hou, X.S., Schleif, W.A., Miller, M.D., Geleziunas, R., and Pessi, A. 2005. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. 102: 12903-12908.
3. Brown, J.H., Kim, K.H., Jun, G., Greenfield, N.J., Dominguez, R., Volkmann, N., Hitchcock-DeGregori, S.E., and Cohen, C. 2001. Deciphering the design of the tropomyosin molecule. Proc. Natl. Acad. Sci. 98: 8496-8501.
4. Bryson, J.W., Betz, S.F., Lu, H.S., Suich, D.J., Zhou, H.X., O'Neil, K.T., and DeGrado, W.F. 1995. Protein design: A hierarchic approach. Science 270: 935-941.
5. Chackerian, B., Long, E.M., Luciw, P.A., and Overbaugh, J. 1997. Human immunodeficiency virus type 1 co-receptors participate in post-entry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71: 3932-3939.
6. Chambers, P., Pringle, C.R., and Easton, A.J. 1990. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71: 3075-3080.
7. Chan, D.C. and Kim, P.S. 1998. HIV entry and its inhibition. Cell 93: 681-684.
8. Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
9. Chan, D.C., Chutkowski, C.T., and Kim, P.S. 1998. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. 95: 15613-15617.
10. Chen, C.H., Matthews, T.J., McDanal, C.B., Bolognesi, D.P., and Greenberg, M.L. 1995. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J. Virol. 69: 3771-3777.
11. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: Programs for X-ray crystallography. Acta Crystallogr. D50: 760-763.
12. Dauter, Z., Dauter, M., and Rajashankar, K.R. 2000. Novel approach to phasing proteins: Derivitization by short cryo-soaking with halides. Acta Crystallogr. D56: 232-237.
13. Delwart, E.L., Mosialos, G., and Gilmore, T. 1990. Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res. Hum. Retroviruses 6: 703-706.
14. Dwyer, J.J., Hasan, A., Wilson, K.L., White, J.M., Matthews, T.J., and Delmedico, M.K. 2003. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42: 4945-4953.
15. Earl, P.L., Doms, R.W., and Moss, B. 1990. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. 87: 648-652.
16. Eckert, D.M. and Kim, P.S. 2001. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. 98: 11187-11192.
17. Eckert, D.M., Malashkevich, V.N., Hong, L.H., Carr, P.A., and Kim, P.S. 1999. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99: 103-115.
18. Edelhoch, H. 1967. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954.
19. Ferrer, M., Kapoor, T.M., Strassmaier, T., Weissenhorn, W., Skehel, J.J., Oprian, D., Schreiber, S.L., Wiley, D.C., and Harrison, S.C. 1999. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat. Struct. Biol. 6: 953-960.
20. French, G.S. and Wilson, K.S. 1978. On the treatment of negative intensity observations. Acta Crystallogr. A34: 517-525.
21. Gallaher, W.R., Ball, J.M., Garry, R.F., Griffin, M.C., and Montelaro, R.C. 1989. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 5: 431-440.
22. Greenberg, M.L. and Cammack, N. 2004. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54: 333-340.
23. Hao, Q., Gu, Y.X., Zheng, C.D., and Fan, H.F. 2000. OASIS: A computer program for breaking phase ambiguity in one-wavelength anomalous scattering or single isomorphous substitution (replacement) data. J. Appl. Crystallogr. 33: 980-981.
24. Helseth, E., Olshevsky, U., Furman, C., and Sodroski, J. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65: 2119-2123.
25. Hu, Q.X., Barry, A.P., Wang, Z.X., Connolly, S.M., Peiper, S.C., and Greenberg, M.L. 2000. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74: 11858-11872.
26. Jiang, S., Lin, K., Strick, N., and Neurath, A.R. 1993. HIV-1 inhibition by a peptide. Nature 365: 113.
27. Judice, J.K., Tom, J.Y., Huang, W., Wrin, T., Vennari, J., Petropoulos, C.J., and McDowell, R.S. 1997. Inhibition of HIV type 1 infectivity by constrained α-helical peptides: Implications for the viral fusion mechanism. Proc. Natl. Acad. Sci. 94: 13426-13430.
28. Karlsson, R. and Falt, A. 1997. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J. Immunol. Methods 200: 121-133.
29. Kimpton, J. and Emerman, M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66: 2232-2239.
30. Laue, T.M., Shah, B.D. Ridgeway, T.M., and Pelletier, S.L. 1992. Analytical ultracentrifugation in biochemistry and polymer science. The Royal Society of London, Cambridge, UK.
31. Lawless, M.K., Barney, S., Guthrie, K.I., Bucy, T.B., Petteway Jr., S.R., and Merutka, G. 1996. HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically active peptides from gp41. Biochemistry 35: 13697-13708.
32. Lawless-Delmedico, M.K., Sista, P., Sen, R., Moore, N.C., Antczak, J.B., White, J.M., Greene, R.J., Leanza, K.C., Matthews, T.J., and Lambert, D.M. 2000. Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complex. Biochemistry 39: 11684-11695.
33. Liu, J., Shu, W., Fagan, M.B., Nunberg, J.H., and Lu, M. 2001. Structural and functional analysis of the HIV gp41 core containing an Ile573 to Thr substitution: Implications for membrane fusion. Biochemistry 40: 2797-2807.
34. CCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J. Biol. Chem. 276: 29485-29489.
35. Louis, J.M., Nesheiwat, I., Chang, L., Clore, G.M., and Bewley, C.A. 2003. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 278: 20278-20285.
36. Lu, M., Blacklow, S.C., and Kim, P.S. 1995. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2: 1075-1082.
37. Lu, M., Stoller, M.O., Wang, S., Liu, J., Fagan, M.B., and Nunberg, J.H. 2001. Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J. Virol. 75: 11146-11156.
38. Luftig, M.A., Mattu, M., Di Giovine, P., Geleziunas, R., Hrin, R., Barbato, G., Bianchi, E., Miller, M.D., Pessi, A., and Carfi, A. 2006. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat. Struct. Mol. Biol. 13: 740-747.
39. Lupas, A., Van Dyke, M., and Stock, J. 1991. Predicting coiled coils from protein sequences. Science 252: 1162-1164.
40. McRee, D.E. 1999. XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125: 156-165.
41. Miller, M.D., Geleziunas, R., Bianchi, E., Lennard, S., Hrin, R., Zhang, H., Lu, M., An, Z., Ingallinella, P., Finotto, M., et al. 2005. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. 102: 14759-14764.
42. Mische, C.C., Yuan, W., Strack, B., Craig, S., Farzan, M., and Sodroski, J. 2005. An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor. Virology 338: 133-143.
43. Morrison, T.G. 1988. Structure, function, and intracellular processing of paramyxovirus membrane proteins. Virus Res. 10: 113-135.
44. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. 1997. Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr. D53: 240-255.
45. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
46. Perrakis, A., Morris, R., and Lamzin, V.S. 1999. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6: 458-463.
47. Pinter, A., Honnen, W.J., Tilley, S.A., Bona, C., Zaghouani, H., Gorny, M.K., and Zolla-Pazner, S. 1989. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63: 2674-2679.
48. Rimsky, L.T., Shugars, D.C., and Matthews, T.J. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72: 986-993.
49. Root, M.J., Kay, M.S., and Kim, P.S. 2001. Protein design of an HIV-1 entry inhibitor. Science 291: 884-888.
50. Shugars, D.C., Wild, C.T., Greenwell, T.K., and Matthews, T.J. 1996. Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 70: 2982-2991.
51. Thomas, D.J., Wall, J.S., Hainfeld, J.F., Kaczorek, M., Booy, F.P., Trus, B.L., Eiserling, F.A., and Steven, A.C. 1991. gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains. J. Virol. 65: 3797-3803.
52. Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley, D.C. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
53. Weissenhorn, W., Dessen, A., Calder, L.J., Harrison, S.C., Skehel, J.J., and Wiley, D.C. 1999. Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. 16: 3-9.
54. Weng, Y. and Weiss, C.D. 1998. Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 72: 9676-9682.
55. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. 1992. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. 89: 10537-10541.
56. Wild, C., Greenwell, T., and Matthews, T. 1993. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9: 1051-1053.
57. Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B., and Matthews, T.J. 1994. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. 91: 9770-9774.
58. Wolf, E., Kim, P.S., and Berger, B. 1997. MultiCoil: A program for predicting two- and three-stranded coiled coils. Protein Sci. 6: 1179-1189.
59. Yao, J.-X. 1981. On the application of phase relationships to complex structures XVIII. RANTAN - random MULTAN. Acta Crystallogr. A37: 642-644.